Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TACR3 | P29371 | 3/20 | 0.37 |
| ▸ | TACR2 | P21452 | 2/20 | 0.37 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973564 | 0.87 | TACR3 (0.46) | ALDH1A1KMT2ATACR3TACR2MEN1 | |
| SCHEMBL1974280 | 0.83 | ALDH1A1 (0.46) | ALDH1A1HDAC1KMT2APOLBTACR3 | |
| SCHEMBL1975767 | 0.83 | RIPK1 (0.42) | ALDH1A1KMT2ATACR3MEN1OPRM1 | |
| SCHEMBL1974248 | 0.82 | MEN1 (0.41) | ALDH1A1KMT2ATACR3MEN1 | |
| SCHEMBL1975073 | 0.82 | SMYD3 (0.40) | ALDH1A1KMT2ATACR3MEN1 | |
| SCHEMBL10150961 | 0.80 | PPARG (0.40) | KMT2AGPR139CNR2MEN1LMNA | |
| SCHEMBL10150603 | 0.79 | CNR1 (0.44) | ALDH1A1HDAC1KMT2APOLBCNR2 | |
| SCHEMBL1974289 | 0.78 | TACR3 (0.40) | ALDH1A1KMT2ATACR3TACR2MEN1 | |
| SCHEMBL1974509 | 0.77 | CTSA (0.33) | ALDH1A1KMT2ATACR3TACR2MEN1 | |
| SCHEMBL1974430 | 0.77 | PKM (0.39) | ALDH1A1KMT2ATACR3TACR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011072691-A1 | PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | claimed |
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2011-06-16 | — | — | US | claimed |
| WO-2011072691-A1 | PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | KCNK3, GRIK3, KCND3 | ALDH1A1 2028/4885HDAC1 2683/4885KMT2A 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.